JP2022553922A5 - - Google Patents
Info
- Publication number
- JP2022553922A5 JP2022553922A5 JP2022522002A JP2022522002A JP2022553922A5 JP 2022553922 A5 JP2022553922 A5 JP 2022553922A5 JP 2022522002 A JP2022522002 A JP 2022522002A JP 2022522002 A JP2022522002 A JP 2022522002A JP 2022553922 A5 JP2022553922 A5 JP 2022553922A5
- Authority
- JP
- Japan
- Prior art keywords
- chain variable
- antibody
- variable region
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025019263A JP2025069432A (ja) | 2019-10-11 | 2025-02-07 | ４－１ｂｂに結合する抗体およびその用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962913744P | 2019-10-11 | 2019-10-11 | |
| US62/913,744 | 2019-10-11 | ||
| PCT/CN2020/119388 WO2021068841A1 (en) | 2019-10-11 | 2020-09-30 | Antibodies binding 4-1bb and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025019263A Division JP2025069432A (ja) | 2019-10-11 | 2025-02-07 | ４－１ｂｂに結合する抗体およびその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022553922A JP2022553922A (ja) | 2022-12-27 |
| JP2022553922A5 true JP2022553922A5 (enExample) | 2023-05-10 |
| JP7634001B2 JP7634001B2 (ja) | 2025-02-20 |
Family
ID=75382666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522002A Active JP7634001B2 (ja) | 2019-10-11 | 2020-09-30 | ４－１ｂｂに結合する抗体およびその用途 |
| JP2025019263A Pending JP2025069432A (ja) | 2019-10-11 | 2025-02-07 | ４－１ｂｂに結合する抗体およびその用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025019263A Pending JP2025069432A (ja) | 2019-10-11 | 2025-02-07 | ４－１ｂｂに結合する抗体およびその用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11466086B2 (enExample) |
| EP (1) | EP4041772A4 (enExample) |
| JP (2) | JP7634001B2 (enExample) |
| CN (2) | CN114555638B (enExample) |
| WO (1) | WO2021068841A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7634001B2 (ja) * | 2019-10-11 | 2025-02-20 | ナンチン リーズ バイオラブス カンパニー，リミティド | ４－１ｂｂに結合する抗体およびその用途 |
| CN116253799B (zh) * | 2021-09-09 | 2024-04-26 | 广东东阳光药业股份有限公司 | 抗4-1bb的激动型抗体及其应用 |
| WO2023168547A1 (en) * | 2022-03-07 | 2023-09-14 | Adagene Pte. Ltd. | Anti-cd137 antibodies and methods of making and using the same |
| WO2024051752A1 (en) * | 2022-09-06 | 2024-03-14 | I-Mab Biopharma Co., Ltd. | Multispecific constructs and uses thereof |
| JP2026508244A (ja) | 2023-02-22 | 2026-03-10 | ナンジング リーズ バイオラブズ シーオー．， エルティーディー． | 抗Ｎｅｃｔｉｎ－４抗体及びそれを含む多重特異性抗体 |
| AU2024352742A1 (en) * | 2023-09-27 | 2026-04-09 | Nanjing Leads Biolabs Co., Ltd. | Anti-pd-l1 and anti-4-1bb bispecific antibody for treating tumors |
| CN117736330B (zh) * | 2024-01-24 | 2024-05-17 | 上海沙砾生物科技有限公司 | 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用 |
| WO2026061538A1 (zh) * | 2024-09-23 | 2026-03-26 | 南京维立志博生物科技股份有限公司 | 用于治疗恶性肿瘤的抗pd-l1和抗4-1bb双特异性抗体及其药物组合 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| KR20180016972A (ko) * | 2015-02-22 | 2018-02-20 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd137에 결합하는 항체 치료제 |
| CN114181309B (zh) * | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| WO2018045110A1 (en) * | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| ES2981272T3 (es) * | 2016-09-23 | 2024-10-08 | Merus Nv | Moléculas de unión que modulan una actividad biológica expresada por una célula |
| AU2018224094B2 (en) | 2017-02-24 | 2025-04-17 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
| SG11202000198QA (en) * | 2017-08-04 | 2020-02-27 | Genmab As | Binding agents binding to pd-l1 and cd137 and use thereof |
| EP3470426A1 (en) | 2017-10-10 | 2019-04-17 | Numab Therapeutics AG | Multispecific antibody |
| US12202911B2 (en) | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| TWI701259B (zh) | 2017-11-09 | 2020-08-11 | 大陸商上海懷越生物科技有限公司 | ４﹘１ｂｂ抗體及其製備方法和應用 |
| FI3830120T3 (fi) | 2018-07-31 | 2023-06-13 | Pieris Pharmaceuticals Gmbh | CD137:lle ja PD-L1:lle spesifinen uusi fuusioproteiini |
| CN109021107B (zh) | 2018-09-05 | 2020-08-28 | 江苏诺迈博生物医药科技有限公司 | 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒 |
| JP7575100B2 (ja) | 2018-11-13 | 2024-10-29 | ジェイエヌ バイオサイエンシーズ エルエルシー | 免疫細胞活性化のための二重特異性抗体 |
| CN113286825B (zh) | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| JP7634001B2 (ja) * | 2019-10-11 | 2025-02-20 | ナンチン リーズ バイオラブス カンパニー，リミティド | ４－１ｂｂに結合する抗体およびその用途 |
-
2020
- 2020-09-30 JP JP2022522002A patent/JP7634001B2/ja active Active
- 2020-09-30 CN CN202080071050.2A patent/CN114555638B/zh active Active
- 2020-09-30 CN CN202311290309.4A patent/CN117586400A/zh active Pending
- 2020-09-30 WO PCT/CN2020/119388 patent/WO2021068841A1/en not_active Ceased
- 2020-09-30 EP EP20875286.5A patent/EP4041772A4/en active Pending
- 2020-09-30 US US17/038,669 patent/US11466086B2/en active Active
-
2022
- 2022-10-07 US US18/045,133 patent/US20230192862A1/en active Pending
-
2025
- 2025-02-07 JP JP2025019263A patent/JP2025069432A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022553922A5 (enExample) | ||
| CN108136012B (zh) | 靶向分子的抗原结合构建体 | |
| JP2020501531A5 (enExample) | ||
| RU2019116624A (ru) | Новые анти_cd137 антитела и их применение | |
| JP2023549537A5 (enExample) | ||
| JP2021528973A5 (enExample) | ||
| JP2019536470A5 (enExample) | ||
| JP2019533719A5 (enExample) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2011509245A5 (enExample) | ||
| JP2017519759A5 (enExample) | ||
| JP2017532952A5 (enExample) | ||
| HRP20190605T1 (hr) | Protutijela anti-fxi i postupci njihove uporabe | |
| JP2014529610A5 (enExample) | ||
| JP2022549172A5 (enExample) | ||
| JP2025069432A5 (enExample) | ||
| JP2024537323A5 (enExample) | ||
| JP2017537082A5 (enExample) | ||
| JP2024016024A5 (enExample) | ||
| JP2024001073A5 (enExample) | ||
| JP2022545741A5 (enExample) | ||
| JP2023511963A5 (enExample) | ||
| JP2020533965A5 (enExample) | ||
| WO2015105973A1 (en) | ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF | |
| JP2024515560A5 (enExample) |